Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan
This article was originally published in PharmAsia News
YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds
You may also be interested in...
Daiichi Sankyo and Mitsubishi UFJ – with ¥450 million in government backing – launched a fund to develop university venture technology for Daiichi Sankyo’s pipeline.
Prism’s lead compound is already in-licensed by Eisai for cancer indications, and the startup is now looking for a partner for the compound’s fibrosis indications now that Phase I plans are in the works.
Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.